- Home
- RGT vs GNLX Comparison
RGT vs GNLX Comparison
Compare RGT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGT | GNLX |
|---|---|---|
| Founded | 1986 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.4M | 113.6M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | RGT | GNLX |
|---|---|---|
| Price | $14.32 | $3.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 12.6K | ★ 153.2K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ 0.92 | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.40 | $2.29 |
| 52 Week High | $14.99 | $8.54 |
Technical Indicators
Market Signals| Indicator | RGT | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 57.57 |
| Support Level | $12.50 | $2.39 |
| Resistance Level | $14.68 | $3.25 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 48.32 | 55.28 |
Price Performance
Historical ComparisonAbout RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The Fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples and energy. Geographically, it has presence in the United Kingdom, Japan, the United States, Canada, France, Hong Kong and Germany.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.